Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3498 |
Name | pancreatic ductal adenocarcinoma |
Definition | A pancreatic adenocarcinoma that derives_from pancreatic duct cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer pancreatic carcinoma pancreatic adenocarcinoma pancreatic ductal adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
BRAF N486_P490del | Trametinib | pancreatic ductal adenocarcinoma | sensitive | detail... |
ATM R3008C | Fluorouracil + Oxaliplatin + Veliparib | pancreatic ductal adenocarcinoma | no benefit | detail... |
ATM T2333Nfs*40 | Fluorouracil + Oxaliplatin + Veliparib | pancreatic ductal adenocarcinoma | no benefit | detail... |
BRAF N486_P490del | LY3009120 | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
BRAF N486_P490del | LY3009120 + Trametinib | pancreatic ductal adenocarcinoma | sensitive | detail... |
BRAF V600E | Cobimetinib + Gemcitabine + Nab-paclitaxel | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
BRAF V600E | Trametinib + Vemurafenib | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
BRAF V600E | Cobimetinib + Vemurafenib | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
BRAF V600E | Ulixertinib | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
FGFR2 rearrange | Erdafitinib | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
BRAF N486_P490del | Dabrafenib + Trametinib | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
BRAF N486_P490del | Ulixertinib | pancreatic ductal adenocarcinoma | sensitive | detail... |
BRAF N486_P490del | Binimetinib | pancreatic ductal adenocarcinoma | sensitive | detail... |
BRAF N486_P490del | SCH772984 | pancreatic ductal adenocarcinoma | sensitive | detail... |
BRAF N486_P490del | Sorafenib | pancreatic ductal adenocarcinoma | sensitive | detail... |
BRAF N486_P490del | LXH 254 | pancreatic ductal adenocarcinoma | sensitive | detail... |
BRAF V600E | Binimetinib + Cetuximab + Encorafenib | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01647828 | Phase Ib/II | Nab-paclitaxel Gemcitabine Tarextumab | A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer | Completed | USA | 0 |
NCT02042378 | Phase II | Rucaparib | A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | Completed | USA | ISR | 0 |
NCT02101021 | Phase II | Gemcitabine + Nab-paclitaxel Momelotinib | Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma | Terminated | USA | 0 |
NCT02109445 | Phase II | Gemcitabine + Nab-paclitaxel Nirogacestat | Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies | Terminated | USA | 0 |
NCT02241187 | Phase I | Cetuximab + PEGPH20 | Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection | Completed | USA | 0 |
NCT02259114 | Phase I | Birabresib | A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors | Completed | 0 | |
NCT02289898 | Phase II | Demcizumab + Gemcitabine + Nab-paclitaxel | Study of Gemcitabine, Abraxane Plus Placebo Versus Gemcitabine, Abraxane Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma | Completed | USA | GBR | ESP | CAN | BEL | AUS | 0 |
NCT02362048 | Phase II | Acalabrutinib Pembrolizumab | ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT02501902 | Phase I | Nab-paclitaxel + Palbociclib | Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC | Completed | USA | ESP | 0 |
NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02583477 | Phase Ib/II | AZD5069 + Durvalumab Durvalumab + Gemcitabine + Nab-paclitaxel | Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma | Completed | USA | GBR | 0 |
NCT02600949 | Phase I | Pembrolizumab | Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma | Recruiting | USA | 0 |
NCT02672917 | Phase I | MVT-5873 | Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies | Active, not recruiting | USA | 0 |
NCT02705196 | Phase Ib/II | Atezolizumab + Gemcitabine + LOAd703 + Nab-paclitaxel Gemcitabine + LOAd703 + Nab-paclitaxel | LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer | Recruiting | USA | 0 |
NCT02732938 | Phase I | Gemcitabine + Nab-paclitaxel + PF-04136309 | Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i) | Terminated | USA | 0 |
NCT02754726 | Phase II | Cisplatin + Gemcitabine + Nab-paclitaxel + Nivolumab + Paricalcitol | Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT02810418 | Phase Ib/II | LMB-100 LMB-100 + Nab-paclitaxel | Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors | Completed | USA | 0 |
NCT02857270 | Phase I | LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | Completed | USA | FRA | AUS | 1 |
NCT02879318 | Phase II | Gemcitabine + Nab-paclitaxel Durvalumab + Tremelimumab | Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma | Active, not recruiting | CAN | 0 |
NCT02880371 | Phase Ib/II | ARRY-382 + Pembrolizumab | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02921022 | Phase 0 | Gemcitabine + Nab-paclitaxel + PEGPH20 | Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT02942095 | Phase I | Erlotinib + Ixazomib | Study of Ixazomib and Erlotinib in Solid Tumors | Completed | USA | 0 |
NCT02978547 | Phase II | Metformin | The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma (Metformin 001) | Unknown status | CAN | 0 |
NCT02981342 | Phase II | Capecitabine Abemaciclib Gemcitabine Abemaciclib + LY3023414 Abemaciclib + Galunisertib | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | Completed | USA | ISR | GBR | FRA | ESP | BEL | AUS | 1 |
NCT02993731 | Phase III | Gemcitabine + Nab-paclitaxel + Napabucasin Gemcitabine + Nab-paclitaxel | A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P) | Completed | USA | POL | NLD | ITA | FRA | ESP | DEU | CZE | CAN | BEL | AUT | AUS | 8 |
NCT03038477 | Phase II | Durvalumab | A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection | Withdrawn | USA | 0 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03118349 | Phase I | MVT-1075 + MVT-5873 | Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy | Terminated | USA | 0 |
NCT03193190 | Phase Ib/II | Atezolizumab + BKT140 Fluorouracil + Gemcitabine + Leucovorin + Nab-paclitaxel + Oxaliplatin + Pembrolizumab Atezolizumab + PEGPH20 Atezolizumab + Cobimetinib | A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Active, not recruiting | USA | ESP | DEU | 2 |
NCT03264404 | Phase II | Azacitidine + Pembrolizumab | Azacitidine and Pembrolizumab in Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT03412799 | Phase I | Gemcitabine + Nab-paclitaxel + SBP-101 | Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | Completed | USA | AUS | 0 |
NCT03415126 | Phase I | ERAS-007 | A Study of ASN007 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03415854 | Phase II | Cisplatin + Gemcitabine + Nab-paclitaxel + Paricalcitol | Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) (NABPLAGEMD) | Completed | USA | 0 |
NCT03425279 | Phase Ib/II | Mecbotamab Vedotin | CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors | Recruiting | USA | 2 |
NCT03432676 | Phase II | Epacadostat + Pembrolizumab | Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD) | Withdrawn | 0 | |
NCT03435250 | Phase I | AG-270 + Docetaxel AG-270 + Gemcitabine + Nab-paclitaxel AG-270 | Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss | Terminated | USA | FRA | ESP | 0 |
NCT03450018 | Phase Ib/II | Gemcitabine + SLC-0111 | A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX (SLC-0111-17-01) | Terminated | CAN | 0 |
NCT03496662 | Phase Ib/II | Nivolumab BMS-813160 + Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel BMS-813160 + Gemcitabine + Nab-paclitaxel + Nivolumab | BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) | Completed | USA | 0 |
NCT03592888 | Phase I | mDC3/8-KRAS vaccine | DC Vaccine in Pancreatic Cancer | Completed | USA | 0 |
NCT03608631 | Phase I | iExosomes | iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation | Active, not recruiting | USA | 0 |
NCT03610490 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine + MDA autologous tumor-infiltrating lymphocytes | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | Terminated | USA | 0 |
NCT03634332 | Phase II | PEGPH20 + Pembrolizumab | Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC | Unknown status | USA | 0 |
NCT03637491 | Phase II | Avelumab + Binimetinib + Talazoparib Avelumab + Binimetinib | A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | Terminated | USA | BEL | 1 |
NCT03681951 | Phase Ib/II | GSK3145095 GSK3145095 + Pembrolizumab | First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03682289 | Phase II | Ceralasertib + Olaparib Olaparib | Phase II Trial of AZD6738 Alone and in Combination With Olaparib | Recruiting | USA | 0 |
NCT03727880 | Phase II | Defactinib + Pembrolizumab Pembrolizumab | Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | Recruiting | USA | 0 |
NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Completed | USA | NLD | GBR | FRA | FIN | ESP | 0 |
NCT03806309 | Phase II | OSE 2101 Nivolumab + OSE 2101 Fluorouracil + Irinotecan + Leucovorin | Maintenance Therapy With OSE2101 Vaccine Alone or in Combination With Nivolumab, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPAM) | Recruiting | FRA | 0 |
NCT03811652 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | Completed | USA | CAN | 0 |
NCT03871959 | Phase I | Pembrolizumab + Xevinapant | Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma (CATRIPCA) | Completed | FRA | 0 |
NCT03953235 | Phase Ib/II | GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | Completed | USA | 0 |
NCT03979066 | Phase II | Atezolizumab Atezolizumab + PEGPH20 | Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma (NEOiPANC) | Terminated | USA | 0 |
NCT04042480 | Phase I | SGN-CD228A | A Study of SGN-CD228A in Advanced Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | 0 |
NCT04111172 | Phase II | Ad5.F35-hGCC-PADRE | Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies | Suspended | USA | 0 |
NCT04117958 | Phase I | AMG 199 | Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers | Terminated | USA | NLD | FRA | ESP | DEU | AUT | 3 |
NCT04161755 | Phase I | Atezolizumab + Autogene cevumeran + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery | Active, not recruiting | USA | 0 |
NCT04229004 | Phase III | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Gemcitabine + Nab-paclitaxel | A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT04243499 | Phase I | ICT01 | First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) | Recruiting | USA | GBR | FRA | ESP | DEU | BEL | 0 |
NCT04257448 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + Romidepsin Azacitidine + Gemcitabine + Nab-paclitaxel Azacitidine + Gemcitabine + Nab-paclitaxel + Romidepsin Gemcitabine + Nab-paclitaxel Durvalumab + Lenalidomide | Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer (SEPION) | Active, not recruiting | DEU | 0 |
NCT04262388 | Phase II | Durvalumab + Oleclumab | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME) | Withdrawn | CAN | 0 |
NCT04338685 | Phase I | RO7119929 + Tocilizumab | A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases | Completed | USA | ESP | DNK | 3 |
NCT04431258 | Phase Ib/II | ABTL0812 + Fluorouracil + Irinotecan + Oxaliplatin Fluorouracil + Irinotecan + Oxaliplatin | ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study (PanC-ASAP) | Completed | USA | ISR | FRA | ESP | 0 |
NCT04477343 | Phase I | Nivolumab + SX-682 | A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Recruiting | USA | 0 |
NCT04493060 | Phase II | Dostarlimab-gxly + Niraparib | Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT04536077 | Phase II | CDX-1140 + CDX-301 CDX-1140 | Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients | Terminated | USA | 0 |
NCT04581343 | Phase I | Canakinumab + Gemcitabine + Nab-paclitaxel + Spartalizumab | A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients (PanCAN-SR1) | Active, not recruiting | USA | 0 |
NCT04659603 | Phase II | SAR408701 Gemcitabine + SAR408701 | Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors (CARMEN-BT01) | Active, not recruiting | USA | TUR | NLD | HUN | ESP | ARG | 4 |
NCT04672434 | Phase I | Sym021 + Sym024 Sym024 | Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies | Active, not recruiting | USA | CAN | 0 |
NCT04704154 | Phase II | Nivolumab + Regorafenib | A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | Completed | USA | ITA | GBR | FRA | BEL | 3 |
NCT04752696 | Phase II | Fluorouracil + Leucovorin + Liposomal irinotecan + Onvansertib | Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT04753879 | Phase II | Olaparib + Pembrolizumab Capecitabine + Cisplatin + Gemcitabine + Irinotecan + Nab-paclitaxel | Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | Recruiting | USA | 0 |
NCT04809766 | Phase I | Bendamustine FH-TCR-TMSLN Cyclophosphamide + Fludarabine | Mesothelin-Specific T-Cells (FH-TCR-TMSLN) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT04853017 | Phase Ib/II | ELI-002 | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201) | Active, not recruiting | USA | 0 |
NCT04887805 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer | Recruiting | USA | 0 |
NCT04888312 | Phase Ib/II | Fluorouracil + Irinotecan + JNJ-64457107 + Leucovorin + Oxaliplatin | Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients (OPTIMIZE-1) | Active, not recruiting | FRA | ESP | BEL | 0 |
NCT04892017 | Phase Ib/II | DCC-3116 + Sotorasib Binimetinib + DCC-3116 DCC-3116 DCC-3116 + Trametinib | A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors | Recruiting | USA | 0 |
NCT04900818 | Phase I | Givastomig | Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT04907851 | Phase II | Denosumab + RXC004 Denosumab + Pembrolizumab + RXC004 | A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86) | Completed | GBR | AUS | 0 |
NCT04916236 | Phase I | LY3214996 + RMC-4630 | Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA) | Unknown status | NLD | 0 |
NCT04935359 | Phase III | Gemcitabine + Nab-paclitaxel + NIS793 Gemcitabine + Nab-paclitaxel | Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 | Completed | USA | TUR | SWE | SVK | NOR | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUS | 6 |
NCT04943900 | Phase I | BMS-986416 + Nivolumab BMS-986416 | A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | Active, not recruiting | USA | NLD | CAN | BEL | ARG | 2 |
NCT04975217 | Phase I | Fecal microbiota | Fecal Microbial Transplants for the Treatment of Pancreatic Cancer | Recruiting | USA | 0 |
NCT04976634 | Phase II | Belzutifan + Lenvatinib + Pembrolizumab | Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) | Recruiting | USA | NZL | NLD | ISR | FRA | ESP | BEL | AUS | 2 |
NCT04989387 | Phase I | INCA00186 + Retifanlimab INCA00186 + INCB106385 INCA00186 + INCB106385 + Retifanlimab INCA00186 | Study of INCA 0186 in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | NLD | GBR | ESP | BEL | AUT | 0 |
NCT04990037 | Phase I | Fluorouracil + Irinotecan + Leucovorin + Nidanilimab + Oxaliplatin | A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma (CAPAFOUR) | Completed | FRA | ESP | 0 |
NCT05031494 | Phase II | Toripalimab-tpzi + YH003 Gemcitabine + Nab-paclitaxel + Toripalimab-tpzi + YH003 | A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers | Active, not recruiting | USA | AUS | 0 |
NCT05042128 | Phase II | Gemcitabine + Nab-paclitaxel CEND-1 + Gemcitabine + Nab-paclitaxel | The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (ASCEND) | Active, not recruiting | NZL | AUS | 0 |
NCT05052723 | Phase II | Cabozantinib + Pembrolizumab | Cabozantinib and Pembrolizumab in Metastatic Pancreas | Active, not recruiting | USA | 0 |
NCT05055323 | Phase I | Pyrvinium | A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer | Recruiting | USA | 0 |
NCT05074472 | Phase Ib/II | ZB131 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | Completed | USA | 0 |
NCT05121038 | Phase Ib/II | CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab | CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab (CENDIFOX) | Recruiting | USA | 0 |
NCT05254171 | Phase II | Gemcitabine + Nab-paclitaxel + SBP-101 Gemcitabine + Nab-paclitaxel | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (ASPIRE) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 1 |
NCT05298592 | Phase I | BMS-986406 + Nivolumab BMS-986406 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | Completed | USA | ESP | BEL | ARG | 2 |
NCT05307874 | Phase Ib/II | Aldesleukin + ICT01 | Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (EVICTION-2) | Recruiting | FRA | 0 |
NCT05325866 | Phase I | Bemarituzumab | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) | Recruiting | USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 4 |
NCT05442749 | Phase II | Niraparib | Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer (PARPi-PANC) | Withdrawn | FRA | 0 |
NCT05458219 | Phase I | IBI343 | A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | Recruiting | USA | AUS | 1 |
NCT05494866 | Phase I | Cobicistat + Gemcitabine + Nab-paclitaxel | A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients With Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma (IntenSify) | Terminated | DEU | 0 |
NCT05498597 | Phase I | AMT-151 | AMT-151 in Patients With Selected Advanced Solid Tumours | Recruiting | AUS | 1 |
NCT05512377 | Phase II | BI 907828 | Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | Recruiting | USA | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS | 7 |
NCT05546853 | Phase I | Fluorouracil + Irinotecan + Leucovorin + NP137 + Oxaliplatin | Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma (LAP-NET1) | Recruiting | FRA | 0 |
NCT05547321 | Phase I | OMTX705 + Pembrolizumab OMTX705 | Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors. | Recruiting | USA | ESP | 0 |
NCT05558982 | Phase II | Pembrolizumab + Talabostat mesylate | BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (EXPEL PANC) | Recruiting | USA | 0 |
NCT05585320 | Phase Ib/II | IMM-1-104 | A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05605509 | Phase II | Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 | RP-6306 in Patients With Advanced Cancer | Recruiting | CAN | 0 |
NCT05605522 | Phase I | 225Ac-FPI-2059 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | Recruiting | USA | AUS | 0 |
NCT05607953 | Phase I | Pembrolizumab + SD-101 | Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma | Recruiting | USA | 0 |
NCT05630183 | Phase II | Gemcitabine + Nab-paclitaxel Botensilimab + Gemcitabine + Nab-paclitaxel | A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer | Recruiting | USA | 0 |
NCT05631574 | Phase I | BMF-219 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer | Recruiting | USA | 1 |
NCT05642949 | Phase Ib/II | MHB036C | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05669482 | Phase Ib/II | Defactinib + Gemcitabine + Nab-paclitaxel + RO5126766 | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (RAMP205) | Recruiting | USA | 0 |
NCT05720117 | Phase I | PYX-201 | Study of PYX-201 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |
NCT05821556 | Phase II | Capecitabine + Cisplatin + Gemcitabine + Nab-paclitaxel + Simvastatin + Valproic acid Gemcitabine + Nab-paclitaxel + Simvastatin + Valproic acid Gemcitabine + Nab-paclitaxel Capecitabine + Cisplatin + Gemcitabine + Nab-paclitaxel | Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients | Recruiting | ITA | ESP | 0 |
NCT05846516 | Phase I | ATP150 + ATP152 + VSV-GP154 ATP150 + ATP152 + Ezabenlimab + VSV-GP154 | A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02) | Recruiting | USA | CHE | 0 |
NCT05862324 | Phase Ib/II | TAC01-CLDN18.2 | TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3) | Recruiting | USA | CAN | 0 |
NCT05875168 | Phase Ib/II | DS-3939a | First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | Recruiting | USA | FRA | ESP | BEL | 1 |
NCT05922930 | Phase Ib/II | TROP2-CAR/IL15-transduced CBNK cells Cyclophosphamide + Fludarabine | Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer | Recruiting | USA | 0 |
NCT05968326 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Atezolizumab + Autogene cevumeran + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma (IMCODE003) | Recruiting | USA | SWE | GBR | FRA | ESP | DEU | CAN | 0 |
NCT05969041 | Phase I | MT-302 | Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) | Recruiting | AUS | 0 |
NCT05977322 | Phase I | 177Lu-FF58 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | Active, not recruiting | USA | NLD | ITA | ISR | ESP | CHE | 0 |
NCT05983133 | Phase I | SGN-EGFRd2 | A Study of SGN-EGFRd2 in Advanced Solid Tumors | Recruiting | USA | GBR | 0 |
NCT05984602 | Phase I | Canakinumab + Gemcitabine + Nab-paclitaxel + Tislelizumab | A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer | Recruiting | USA | 0 |
NCT06015724 | Phase II | Daratumumab + Nivolumab + QS21 + TG01 | Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer (DARANIVOVAX) | Recruiting | USA | 0 |
NCT06024174 | Phase Ib/II | Adagrasib + BBP-398 + Cetuximab Adagrasib + BBP-398 | A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors | Terminated | USA | ISR | FRA | FIN | AUS | 0 |
NCT06026410 | Phase I | Cabozantinib + KO-2806 Adagrasib + KO-2806 KO-2806 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001) | Recruiting | USA | 0 |
NCT06048484 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Pegfilgrastim AB680 + Etrumadenant + Zimberelimab AB680 + Zimberelimab Zimberelimab | Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma (AIRPanc) | Recruiting | USA | 0 |
NCT06056323 | Phase Ib/II | HB0045 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06059001 | Phase I | Gemcitabine + Nab-paclitaxel + OMO-103 | Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC (OMO-103-02) | Recruiting | ESP | 0 |
NCT06060405 | Phase II | Durvalumab + Oleclumab | Durvalumab and Oleclumab in Resectable PDAC (DORA) | Recruiting | CAN | 0 |
NCT06069778 | Phase Ib/II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + MVT-5873 + Oxaliplatin | Safety, Tolerability, and Efficacy of mFOLFIRINOX +/- BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma | Recruiting | USA | 0 |
NCT06076837 | Phase I | Balstilimab + Botensilimab + Celecoxib + Chloroquine phosphate + Cisplatin + Gemcitabine + Nab-paclitaxel | The Seven Trial: Exploiting the Unfolded Protein Response | Not yet recruiting | USA | 0 |
NCT06084481 | Phase I | ABBV-400 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | Recruiting | USA | ISR | ESP | AUS | 4 |
NCT06105021 | Phase Ib/II | AFNT-211 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | Recruiting | USA | 0 |
NCT06119217 | Phase II | Gemcitabine + Nab-paclitaxel + TTX-030 Gemcitabine + Nab-paclitaxel Budigalimab + Gemcitabine + Nab-paclitaxel + TTX-030 | Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients | Recruiting | USA | ITA | FRA | ESP | AUS | 2 |
NCT06131840 | Phase I | SGN-CEACAM5C | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | Recruiting | USA | SWE | NLD | GBR | ESP | CAN | 0 |
NCT06141031 | Phase Ib/II | C188-9 | Phase 1/2 Trial of Radiotherapy in Combination With TTI-101 in Patients With Borderline Resectable Pancreatic Cancer | Recruiting | USA | 0 |
NCT06158139 | Phase I | iC9-CAR.B7-H3 T-cells | Autologous CAR-T Cells Targeting B7-H3 in PDAC | Recruiting | USA | 0 |
NCT06179160 | Phase I | Cetuximab + INCB161734 + Retifanlimab INCB161734 | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | AUS | 1 |
NCT06194877 | Phase I | BGB3245 + Panitumumab | A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers | Recruiting | USA | AUS | 0 |
NCT06203821 | Phase I | NP137 Fluorouracil + Irinotecan + Leucovorin + NP137 + Oxaliplatin | Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer | Not yet recruiting | USA | 0 |
NCT06205849 | Phase I | JNJ-64457107 | Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer | Recruiting | USA | 0 |
NCT06206876 | Phase I | FL118 | FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma | Not yet recruiting | USA | 0 |
NCT06219941 | Phase II | AZD0901 + Irinotecan AZD0901 + Liposomal irinotecan AZD0901 + Leucovorin AZD0901 + Fluorouracil AZD0901 + Gemcitabine AZD0901 | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | Recruiting | USA | POL | GBR | ESP | CAN | AUS | 7 |
NCT06242691 | Phase II | MK-1200 | Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors | Active, not recruiting | USA | ISR | AUS | 3 |
NCT06255665 | Phase I | JNJ-79032421 | A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors | Recruiting | ESP | 0 |
NCT06305247 | Phase Ib/II | IPN01194 | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | Recruiting | USA | FRA | ESP | 0 |
NCT06330064 | Phase II | Ifinatamab deruxtecan | A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Recruiting | USA | TUR | POL | NLD | ITA | IRL | FRA | ESP | DEU | BRA | BEL | AUS | ARG | 5 |
NCT06334432 | Phase Ib/II | NUV-1511 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06378047 | Phase I | Pembrolizumab | Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer | Recruiting | USA | 0 |
NCT06381154 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Pembrolizumab + Verteporfin | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer | Not yet recruiting | USA | 0 |
NCT06390059 | Phase II | Atezolizumab + Gemcitabine + Nab-paclitaxel | EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma | Recruiting | ESP | 0 |
NCT06393400 | Phase I | Fecal microbiota + Gemcitabine + Nab-paclitaxel | CHemotherapy And Stool Transplant in PDAC (CHASe-PDAC) (CHASe-PDAC) | Not yet recruiting | CAN | 0 |
NCT06398587 | Phase II | Gemcitabine + Nab-paclitaxel + Onvansertib | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma | Withdrawn | USA | 0 |
NCT06428409 | Phase Ib/II | Fluorouracil + Leucovorin + SKB264 SKB264 | A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A) | Recruiting | USA | ITA | GBR | ESP | CHE | CAN | AUS | 5 |
NCT06440005 | Phase I | AGX101 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06445062 | Phase Ib/II | Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin + RMC-6236 Gemcitabine + Nab-paclitaxel + RMC-6236 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + RMC-6236 Cetuximab + RMC-6236 Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + RMC-6236 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Recruiting | USA | 0 |
NCT06447662 | Phase I | PF-07934040 Gemcitabine + Nab-paclitaxel + PF-07934040 Carboplatin + Pembrolizumab + Pemetrexed Disodium + PF-07934040 Pembrolizumab + PF-07934040 Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + PF-07934040 Cetuximab + PF-07934040 Cisplatin + Pembrolizumab + Pemetrexed Disodium + PF-07934040 | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | Recruiting | USA | 1 |
NCT06451497 | Phase I | ZM008 | Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06498518 | Phase II | Gemcitabine + IMM-101 + Pembrolizumab | A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer (PRIMUS006) | Recruiting | GBR | 0 |
NCT06528093 | Phase I | BI 765883 + Gemcitabine + Nab-paclitaxel BI 765883 | A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy | Recruiting | USA | FRA | ESP | DEU | BEL | 1 |
NCT06544655 | Phase I | BMS-986484 + Nivolumab BMS-986484 | A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT06592664 | Phase Ib/II | Gemcitabine + Nab-paclitaxel CEND-1 + Gemcitabine + Nab-paclitaxel | LSTA1 Phase 1b/2a Continuous Infusion Trial in mPDAC (FORTIFIDE) | Not yet recruiting | USA | 0 |
NCT06598007 | Phase Ib/II | CT3001 | A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06598371 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + KSQ-004EX KSQ-004EX | A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors | Not yet recruiting | USA | 0 |
NCT06599502 | Phase Ib/II | AZD0022 + Cetuximab AZD0022 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01) | Recruiting | USA | TUR | POL | NLD | ITA | ESP | CAN | BEL | AUS | 0 |
NCT06625320 | Phase III | Fluorouracil + Leucovorin + Liposomal irinotecan Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Gemcitabine + Nab-paclitaxel RMC-6236 | Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302) | Recruiting | USA | 1 |
NCT06626256 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + STIL101 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | Not yet recruiting | USA | 0 |
NCT06648434 | Phase I | ATI-450 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma | Not yet recruiting | USA | 0 |